Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study

Fineline Cube Dec 9, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) unveiled longer-term results from the pivotal Phase III ASC4FIRST...

Company Drug

Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials

Fineline Cube Dec 9, 2024

Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...

Company Deals

SinoPep-Allsino Biopharmaceutical Partners with Spraying Systems Co. for Peptide API Manufacturing

Fineline Cube Dec 9, 2024

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has announced...

Company Drug

Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation

Fineline Cube Dec 9, 2024

US pharmaceutical giant Merck (NYSE: MRK) has revealed promising data from the Phase II waveLINE-007...

Company Deals

Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange

Fineline Cube Dec 9, 2024

Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based...

Company Drug

AstraZeneca’s Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results

Fineline Cube Dec 9, 2024

At the 66th American Society of Hematology (ASH) annual meeting, UK pharmaceutical major AstraZeneca (AZ,...

Company Drug

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH

Fineline Cube Dec 9, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...

Company Drug

Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study

Fineline Cube Dec 9, 2024

Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I...

Company Drug

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026

Fineline Cube Dec 9, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...

Company Drug

Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial

Fineline Cube Dec 8, 2024

Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...

Company Drug

Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced

Fineline Cube Dec 8, 2024

China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis...

Company Drug

Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer

Fineline Cube Dec 7, 2024

Immunofoco, a biotechnology company specializing in immunotherapy, has announced that its self-developed autologous CAR-T product,...

Company Drug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

Fineline Cube Dec 7, 2024

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...

Company Deals

AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics

Fineline Cube Dec 7, 2024

US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...

Company Drug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

Fineline Cube Dec 7, 2024

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...

Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Dec 7, 2024

The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...

Company Drug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Fineline Cube Dec 7, 2024

Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...

Company Drug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Fineline Cube Dec 6, 2024

The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...

Company Deals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

Fineline Cube Dec 6, 2024

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...

Company Deals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Fineline Cube Dec 6, 2024

GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...

Posts pagination

1 … 258 259 260 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.